bearish
Sipai Health Technology (314.HK) - Unjustified Valuation and Problematic Business Model
The sustainability/stability of Sipai’s performance/growth potential is worrying. Weak profitability make Sipai hard to be breakeven.High valuation is hard to sustain due to problematic business model
245 Views29 Mar 2023 09:15
SUMMARY(Sign Up to Access)
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- Unlimited Research Summaries
- Personalised Alerts
- Custom Watchlists
- Company Analytics & News
- Events & Webinars
Trusted by:
Already have an account? Sign In Now
Full Insight
(Paid Plans Only)
Discussions
(Paid Plans Only)
Top Quartile
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
Price Chart(Sign Up to Access)
- Sipai Health Technology (314.HK) - Unjustified Valuation and Problematic Business Model29 Mar 2023
- CanSino Biologics (6185.HK) 2022 Results - It Is Time to Reassess CanSino and Its Future Prospects29 Mar 2023
- Ping An Healthcare and Technology Company Limited (1833.HK)- To Turn Things Around or to Fail Again?15 Mar 2023
- JD Health (6618.HK) - It's Time to Reassess the Business Prospects and Valuation09 Mar 2023
x